Paul Kuentz

Dr. Paul Kuentz

Oncobiologie Génétique Bioinformatique, PCBio
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Neuron
Verified
Journal Article
Closed access
ALAshley L. Lennox
Ashley L. Lennox
MHMariah L. Hoye
Mariah L. Hoye
RJRuiji Jiang
Ruiji Jiang
BJBethany L. Johnson-Kerner
Bethany L. Johnson-Kerner
LSLindsey A. Suit
Lindsey A. Suit
ESElliott H. Sherr
Elliott H. Sherr

1 June 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
SNSophie Nambot
Sophie Nambot
JTJulien Thevenon
Julien Thevenon
PKPaul Kuentz
Paul Kuentz
YDYannis Duffourd
Yannis Duffourd
ETEmilie Tisserant
Emilie Tisserant
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet

22 October 2018 in Brain
Verified
Journal Article
Closed access
CMCarla Marini
Carla Marini
APAlessandro Porro
Alessandro Porro
ARAgnès Rastetter
Agnès Rastetter
CDCarine Dalle
Carine Dalle
IRIlaria Rivolta
Ilaria Rivolta
CDChristel Depienne
Christel Depienne
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels control neuronal excitability and their dysfunction has been linked to epileptogenesis but few individuals with neurological disorders related to variants altering HCN channels have been reported so far. In 2014, we described five individuals with epileptic encephalopathy due to de novo HCN1 variants. To delineate HCN1-related disorders and investigate genotype-phenotype correlations further, we assembled a cohort of 33 unpublished patients with novel pathogenic or likely pathogenic variants: 19 probands carrying 14 different de novo mutations and four families with dominantly inherited variants segregating with epilepsy in 14 individuals, but not penetrant in six additional individuals. Sporadic patients had epilepsy with median onset at age 7 months and in 36% the first seizure occurred during a febrile illness. Overall, considering familial and sporadic patients, the predominant phenotypes were mild, including genetic generalized epilepsies and genetic epilepsy with febrile seizures plus (GEFS+) spectrum. About 20% manifested neonatal/infantile onset otherwise unclassified epileptic encephalopathy. The study also included eight patients with variants of unknown significance: one adopted patient had two HCN1 variants, four probands had intellectual disability without seizures, and three individuals had missense variants inherited from an asymptomatic parent. Of the 18 novel pathogenic missense variants identified, 12 were associated with severe phenotypes and clustered within or close to transmembrane domains, while variants segregating with milder phenotypes were located outside transmembrane domains, in the intracellular N- and C-terminal parts of the channel. Five recurrent variants were associated with similar phenotypes. Using whole-cell patch-clamp, we showed that the impact of 12 selected variants ranged from complete loss-of-function to significant shifts in activation kinetics and/or voltage dependence. Functional analysis of three different substitutions altering Gly391 revealed that these variants had different consequences on channel biophysical properties. The Gly391Asp variant, associated with the most severe, neonatal phenotype, also had the most severe impact on channel function. Molecular dynamics simulation on channel structure showed that homotetramers were not conducting ions because the permeation path was blocked by cation(s) strongly complexed to the Asp residue, whereas heterotetramers showed an instantaneous current component possibly linked to deformation of the channel pore. In conclusion, our results considerably expand the clinical spectrum related to HCN1 variants to include common generalized epilepsy phenotypes and further illustrate how HCN1 has a pivotal function in brain development and control of neuronal excitability.

1 September 2017 in Genetics in Medicine
Verified
Journal Article
Closed access
PKPaul Kuentz
Paul Kuentz
JSJudith St-Onge
Judith St-Onge
YDYannis Duffourd
Yannis Duffourd
JCJean-Benoît Courcet
Jean-Benoît Courcet
VCVirginie Carmignac
Virginie Carmignac
JRJean-Baptiste Rivière
Jean-Baptiste Rivière

1 February 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
FVFlorian Villegas
Florian Villegas
DLDaphné Lehalle
Daphné Lehalle
DMDaniela Mayer
Daniela Mayer
MRMelanie Rittirsch
Melanie Rittirsch
MSMichael B. Stadler
Michael B. Stadler
JBJoerg Betschinger
Joerg Betschinger

31 May 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EEElias ElInati
Elias ElInati
PKPaul Kuentz
Paul Kuentz
CRClaire Redin
Claire Redin
SJSara Jaber
Sara Jaber
FMFrauke Vanden Meerschaut
Frauke Vanden Meerschaut
SVStéphane Viville
Stéphane Viville
To date, mutations in two genes, SPATA16 and DPY19L2, have been identified as responsible for a severe teratozoospermia, namely globozoospermia. The two initial descriptions of the DPY19L2 deletion lead to a very different rate of occurrence of this mutation among globospermic patients. In order to better estimate the contribution of DPY19L2 in globozoospermia, we screened a larger cohort including 64 globozoospermic patients. Twenty of the new patients were homozygous for the DPY19L2 deletion, and 7 were compound heterozygous for both this deletion and a point mutation. We also identified four additional mutated patients. The final mutation load in our cohort is 66.7% (36 out of 54). Out of 36 mutated patients, 69.4% are homozygous deleted, 19.4% heterozygous composite and 11.1% showed a homozygous point mutation. The mechanism underlying the deletion is a non-allelic homologous recombination (NAHR) between the flanking low-copy repeats. Here, we characterized a total of nine breakpoints for the DPY19L2 NAHR-driven deletion that clustered in two recombination hotspots, both containing direct repeat elements (AluSq2 in hotspot 1, THE1B in hotspot 2). Globozoospermia can be considered as a new genomic disorder. This study confirms that DPY19L2 is the major gene responsible for globozoospermia and enlarges the spectrum of possible mutations in the gene. This is a major finding and should contribute to the development of an efficient molecular diagnosis strategy for globozoospermia.